

[Thermo Fisher, Aesku sign distribution agreement](#)

written by CAP TODAY
February 9, 2024

February 2024—Thermo Fisher Scientific announced an exclusive distribution agreement with Aesku Group to market, sell, and support Aesku’s portfolio of FDA-cleared immunofluorescence products, automated instruments, and software in the United States. The agreement expands Thermo Fisher’s immunology product portfolio of Elia autoimmune diagnostics, ImmunoCap allergy diagnostics, and Phadia systems to include complementary reagents and systems from Aesku.



©2026 CAP TODAY, all rights reserved.

[Sekisui, Aptitude partner to provide POC COVID test](#)

written by CAP TODAY
February 9, 2024

February 2024—Sekisui Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 test in the United States. The EUA-approved, single-use molecular in vitro diagnostic test is for the qualitative detection of nucleic acid from SARS-CoV-2 using anterior nasal swab and saliva samples.



©2026 CAP TODAY, all rights reserved.

BioMérieux acquires software company Lumed

written by CAP TODAY
February 9, 2024

February 2024—BioMérieux has acquired the entire share capital of software company Lumed, increasing its stake from 16 to 100 percent. The acquisition of 84 percent of the capital represents an investment of about \$9.75 million.



©2026 CAP TODAY, all rights reserved.

Fujirebio introduces pTau 217 plasma assay

written by CAP TODAY
February 9, 2024

February 2024—Fujirebio announced the availability of its Lumipulse G pTau 217 plasma assay for the fully automated Lumipulse G immunoassay systems. The chemiluminescent enzyme immunoassay provides a quantitative measurement of pTau 217 in human K₂EDTA plasma within 35 minutes. The assay is for research use only.



©2026 CAP TODAY, all rights reserved.

[TechLab test detects *C. difficile* infection](#)

written by CAP TODAY

February 9, 2024

February 2024—TechLab’s C. Diff Quik Chek Complete test is a rapid membrane enzyme immunoassay for the simultaneous detection of *Clostridium difficile* glutamate dehydrogenase antigen and toxins A and B in a single reaction well. Results are available in less than 30 minutes.



©2026 CAP TODAY, all rights reserved.

[Roche launches next-generation qPCR system](#)

written by CAP TODAY

February 9, 2024

February 2024—Roche launched the LightCycler Pro system, designed and labeled for research and in vitro diagnostic workflows. Enhancements of this LightCycler system include a new vapor chamber for temperature uniformity across the block, new and improved software algorithms, and updated software and user interface. Users can develop their own tests or choose from a portfolio of more than 200 LightMix modular research assays and more than 60 LightMix CE-IVD assays from Roche subsidiary TIB Molbiol.



©2026 CAP TODAY, all rights reserved.

Qiagen STI assay cleared for use on NeuMoDx systems

written by CAP TODAY
February 9, 2024

February 2024—Qiagen announced FDA clearance of the NeuMoDx CT/NG assay 2.0 for its NeuMoDx 96 and 288 integrated PCR-based clinical molecular testing systems in the United States. The assay is designed for direct detection of asymptomatic and symptomatic bacterial infections for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. Results are delivered in about an hour.



©2026 CAP TODAY, all rights reserved.

Flagship, Offspring partner to provide assay development services

written by CAP TODAY
February 9, 2024

February 2024—Flagship Biosciences and Offspring Biosciences announced a strategic partnership to provide a comprehensive suite of preclinical and clinical services. The partnership allows the companies to leverage their combined expertise in preclinical and clinical trial assays to provide their drug development partners an end-to-end solution within North America and Europe.



©2026 CAP TODAY, all rights reserved.

[Health Canada approves Corista DP3 platform](#)

written by CAP TODAY

February 9, 2024

Feb. 7, 2024—Corista announced it has received a class II medical device license from Health Canada for its DP3 platform, a web-based image-management system for digital pathology.



©2026 CAP TODAY, all rights reserved.

[CellaVision, Sysmex sign strategic alliance agreement](#)

written by CAP TODAY

February 9, 2024

Feb. 6, 2024—CellaVision and Sysmex announced a strategic alliance agreement that expands their mutual commitment until 2038.



©2026 CAP TODAY, all rights reserved.